Warby Parker Inc. (WRBY)
USD 14.35
(0.6%)
USD 14.35
(0.6%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -71.99 Million USD | 35.26% |
| 2022 | -111.2 Million USD | 22.59% |
| 2021 | -143.66 Million USD | -158.23% |
| 2020 | -55.63 Million USD | -3245.28% |
| 2019 | -1.66 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -8.95 Million USD | -74.68% |
| 2024 Q1 | -5.12 Million USD | 76.23% |
| 2023 Q4 | -21.56 Million USD | -9.12% |
| 2023 Q3 | -19.76 Million USD | -8.43% |
| 2023 Q2 | -18.23 Million USD | -46.66% |
| 2023 Q1 | -12.43 Million USD | 42.75% |
| 2023 FY | -71.99 Million USD | 35.26% |
| 2022 Q3 | -23.67 Million USD | 26.21% |
| 2022 Q2 | -32.08 Million USD | 4.92% |
| 2022 Q1 | -33.74 Million USD | 26.48% |
| 2022 FY | -111.2 Million USD | 22.59% |
| 2022 Q4 | -21.71 Million USD | 8.29% |
| 2021 Q4 | -45.89 Million USD | 50.1% |
| 2021 FY | -143.66 Million USD | -158.23% |
| 2021 Q3 | -91.97 Million USD | -944.27% |
| 2021 Q2 | -8.8 Million USD | -391.56% |
| 2021 Q1 | 3.02 Million USD | 159.04% |
| 2020 Q4 | -5.11 Million USD | 87.62% |
| 2020 Q3 | -41.33 Million USD | -800.45% |
| 2020 Q1 | -4.59 Million USD | 0.0% |
| 2020 Q2 | -4.59 Million USD | 0.0% |
| 2020 FY | -55.63 Million USD | -3245.28% |
| 2019 FY | -1.66 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alcon Inc. | 1.03 Billion USD | 106.929% |
| AptarGroup, Inc. | 404.01 Million USD | 117.82% |
| Baxter International Inc. | 390 Million USD | 118.461% |
| Becton, Dickinson and Company | 2.42 Billion USD | 102.969% |
| Bausch + Lomb Corporation | 130 Million USD | 155.382% |
| Haemonetics Corporation | 164.88 Million USD | 143.665% |
| Envista Holdings Corp | 31.5 Million USD | 328.559% |
| ResMed Inc. | 1.31 Billion USD | 105.455% |
| Teleflex Incorporated | 506.31 Million USD | 114.22% |
| West Pharmaceutical Services, Inc. | 676 Million USD | 110.65% |